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Background: Cholesterol plays an important role in cancer development, drug resistance and chemoimmuno-sensitivity.
Statins, cholesterol lowering drugs, can induce apoptosis, but also negatively interfere with CD-20 and
rituximab-mediated activity. Our goal is to identify the alternative targets that could reduce cholesterol levels
but do not interfere with CD-20 in chemo immunotherapy of chronic lymphocytic leukemia (CLL).
Methods: MEC-2 cells, a CLL cell line, and the peripheral blood mononuclear cells (PBMCs) from CLL patients
were treated with cholesterol lowering agents, and analyzed the effect of these agents on cholesterol levels,
CD-20 expression and distribution, and cell viability in the presence or absence of fludarabine, rituximab or their
combinations.
Results: We found that MEC-2 cells treated with cholesterol lowering agents (BIBB-515, YM-53601 or TAK-475)
reduced 20% of total cellular cholesterol levels, but also significantly promoted CD-20 surface expression.
Furthermore, treatment of cells with fludarabine, rituximab or their combinations in the presence of BIBB-515,
YM-53601 or TAK-475 enhanced MEC-2 cell chemoimmuno-sensitivity measured by cell viability. More importantly, these
cholesterol lowering agents also significantly enhanced chemoimmuno-sensitivity of the PBMCs from CLL patients.
Conclusion: Our data demonstrate that BIBB-515, YM53601 and TAK-475 render chemoimmuno-therapy resistant
MEC-2 cells sensitive to chemoimmuno-therapy and enhance CLL cell chemoimmuno-sensitivity without CD-20
epitope presentation or its downstream signaling. These results provide a novel strategy which could be applied to
CLL treatment.
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Chronic lymphocytic leukemia (CLL) is the most preva-
lent hematologic malignancy affecting Caucasian adults in
Western countries. In the United States, about 15,000 new
cases are diagnosed every year [1]. CLL is characterized
by the accumulation of mature CD5, CD19, and CD23
B-lymphocytes in peripheral blood, bone marrow, lymph
nodes and spleen [2]. The disease typically occurs in eld-
erly patients (the average age at the time of diagnosis is* Correspondence: freterc@slu.edu; chunfahuang@slu.edu
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article, unless otherwise stated.around 72 years). Overall survival at 5 and 10 years ranges
between 87% and 73% for low-risk patients and 29% and
16% for high risk patients [3]. CLL is widely heteroge-
neous in terms of progression, therapeutic response and
outcome [4]. Approximately one-third of patients with
CLL survive many years without requiring treatment,
whereas others need multiple therapies early in the course
of the disease [5]. Although the entire pathogenesis of
CLL has not been elucidated, the widely held concept is
that CLL is associated with a defective regulation of apop-
tosis, rather than uncontrolled cell proliferation [6].
Over the last three decades, chlorambucil has been the
mainstay for the treatment of CLL; however, the completeentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Purine analogues, particularly fludarabine, are effective
agents to treat CLL, resulting in a higher complete
response rate than chlorambucil or alkylating-based
chemotherapies (20-30% versus 10%) and a longer disease-
free interval; survival, however, is not prolonged [10].
Rituximab and alemtuzumab also result in a higher
complete response rate than chlorambucil in chemonaïve
patients [11,12]. Recent advances have now moved
away from mono-therapy to combination including the
chemoimmuno-therapy [13-17]. The combination of
fludarabine, cyclophosphamide and rituximab treatment
achieves complete responses in only 24% to 39% of
patients [15,16]. Bendamustine, an alkylating agent, plus
rituximab is the other commonly used regimen for CLL,
achieving a response rate of 88% and a complete response
rate of 26% [7]. In spite of some progress in therapy, CLL
is still considered an incurable disease because most
patients generally relapse and eventually develop drug-
resistance [4]. It is clear that new approaches to over-
coming drug-resistance and potentiating the action of
conventional therapy are urgently needed.
Cholesterol contributes to chemotherapy resistance in
hepatocellular carcinoma [18], breast cancer cells [19]
and prostate cancer cells [20]. Statins are inhibitors of 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) re-
ductase which catalyzes the conversion of HMG-CoA
into mevalonate, a rate-limiting step in the cholesterol
biosynthetic pathway [21]. Statins are commonly prescribed
medications that lower serum cholesterol and prevent
cardiovascular diseases [22,23]. Beyond their cholesterol-
lowering properties, statins have also been shown to in-
duce apoptosis through extrinsic and intrinsic pathways
[24-26], and exhibit important antitumor activity in colo-
rectal cancer, breast cancer, lung cancer, prostate cancer,
pancreatic cancer and many other malignancies [27-29].
Although statins can induce apoptosis of acute myeloge-
nous leukemia cell lines [30] and CLL cells [31], they are
unsuitable for CLL therapy because statins interfere with
the detection of CD-20 and impair rituximab-mediated
complement-dependent cytotoxicity [32].
To avoid the negative interference of statins with
CD-20 molecules and rituximab-mediated activity and
to explore whether cholesterol levels contribute to
chemoimmuno-sensitivity and drug-resistance of can-
cer cells, we chose several agents that inhibit squalene
synthase or oxidosqualene cyclase, downstream steps in
the cholesterol biosynthetic pathway, and used a CLL
cell line (MEC-2) and the peripheral blood mononuclear
cells (PBMCs) from CLL patients to investigate the
effect of cholesterol lowering agents on the cholesterol
levels, CD-20 expression and distribution, and cell via-
bility with fludarabine, rituximab or their combinations.
Our results indicate that the inhibitors of squalene synthaseor oxidosqualene cyclase can significantly enhance CLL
cell chemoimmuno-sensitivity.
Results
Effect of chemoimmuno-therapeutic drugs in MEC-2 cell
viability and apoptosis
To investigate whether chemoimmuno-sensitivity of
CLL cells could be altered, we chose MEC-2 cells, a
fludarabine- and rituximab-insensitive CLL cell line.
Cell viability, which indicates complement-dependent
cytotoxicity that contributes significantly to clinical
efficacy, was assessed by the MTT assay or Trypan blue
staining after treatment. Figure 1A illustrates the dose
effect of either fludarabine or rituximab on MEC-2 cell
viability. At lower concentrations (<10 μM fludarabine
or 10 μg/ml rituximab), fludarabine and rituximab have
similar patterns in response to reduce cell viability. Higher
concentrations demonstrate fludarabine cytotoxicity. Two
different methods (MTT assay and Trypan blue staining)
show similar results with exposure of MEC-2 cells to
10 μM fludarabine, 10 μg/ml rituximab or their combi-
nations for 3 days. They caused about 28%, 25% or 50%
reduction of cell viability, respectively (Figure 1B). To
further determine whether the reduction of cell viability
in drug-treated cells is due to cell growth arrest or
apoptosis, we analyzed DNA fragmentation as a result
of the signature events of apoptosis. Figure 1C clearly
shows that treatment of MEC-2 cells with the chemoim-
muno-therapeutic drugs increases DNA fragmentation.
These results demonstrate that chemo- or immuno-
therapeutic drugs induce MEC-2 apoptosis.
Lovastatin enhances chemo-sensitivity in fludarabine-treated
MEC-2 cells
Earlier studies indicated that cholesterol biosynthesis
(Figure 2) is mandatory for cellular growth and has been
implicated in various aspects of tumor development and
progression [33-35]. Certain classes of drugs, such as
statins, inhibit mevalonate metabolism and exhibit growth
inhibitory and pro-apoptotic properties as well as antitu-
mor activity [27-29,36]. Next, we tested the effect of
lovastatin on cholesterol metabolism and cell viability
in chemoimmuno-therapeutic drug-treated MEC-2 cells.
Figure 3A shows that incubation with 5 μM lovastatin for
3 days reduced cellular cholesterol levels by 30%. In cell
treated with lovastatin, fludarabine and lovastatin plus
fludarabine, cell viability was 75, 80, and 57% of control,
respectively. However, lovastatin had little effect in the
cells treated with rituximab alone (Figure 3B, middle
panel). The results indicate that lovastatin may interfere
with CD-20 and rituximab-mediated activity. One recent
report showed that statins induce conformational changes
of CD20 and impair rituximab-mediated complement-
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Figure 1 Effect of chemoimmuno-therapeutic drugs on MEC-2
cell viability and apoptosis. A) MEC-2 cells were treated with
different concentration of fludarabine (Flu) or rituximab (Rit) (n = 16) for
3 days, and cell viability was analyzed by MTT assay. B) MEC-2 cells
were treated with 10 μM fludarabine, 10 μg/ml rituximab or their
combinations for 3 days, and analyzed cell viability by either MTT assay
(n = 16) or Trypan blue staining (n = 4) and DNA fragmentation (C).
The DNA fragmentation represents three experiments performed with
duplicate samples. The values of the treated groups were statistically
different from the untreated control group. Con: control.
*P < 0.05. **P < 0.01.
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chemoimmuno-sensitivity
To identify novel agents that not only block cholesterol
biosynthesis and enhance chemoimmuno-sensitivity,
but also avoid the interference with CD-20 and rituximab-
mediated activity, we targeted squalene synthase and oxi-
dosqualene cyclase which are further downstream steps in
cholesterol biosynthetic pathway (Figure 2). YM-53601 is
a novel squalene synthase inhibitor that reduces plasma
cholesterol and triglyceride levels in several animal species
[37]. BIBB-515 is a selective inhibitor of 2,3-oxidosqualene
cyclase and inhibits LDL production in both normolipe-
mic and hyperlipemic hamsters [38]. Figure 4A shows
that treatment of MEC-2 cells with either BIBB-515 or
YM-53601 for 3 days resulted in about 20% decrease in
total cellular cholesterol. By confocal microscopy, we
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Figure 3 Lovastatin lowers cellular cholesterol and enhances chemo-sensitivity. A) MEC-2 cells were treated with 5 μM lovastatin (L) for
3 days, the samples were extracted and analyzed for total cellular cholesterol (n = 5). C, control (no lovastatin). B) MEC-2 cells were treated with
10 μM fludarabine (F), 10 μg/ml rituximab (R) or their combinations (F + R) in the presence or absence of 5 μM lovastatin for 3 days, and analyzed
cell viability by MTT assay (n = 16). The values of lovastatin treatment were statistically different from the controls. *P < 0.05. **P < 0.01.
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BIBB-515 and YM-53601 slightly intensified CD-20 im-
munostaining, and dramatically increased CD-20 mem-
brane association which would, in turn, lead to increased
signaling through CD-20 to downstream pathways. Fur-
ther studies indicated that either BIBB-515 or YM-53601
enhanced chemoimmuno-sensitivity in the cells treated
with fludarabine, rituximab or their combinations. Cell
viability was reduced from 80% to 43% in BIBB-515

























Figure 4 The influence of BIBB-515 and YM-53601 on cholesterol leve
with 10 μM either BIBB-515 (B) or YM-53601 (Y) for 3 days. A) The cells wer
treated with BIBB-515 or YM-53601 samples were statistically different from
The cells were stained for 1 hour with anti-CD-20 APC antibody and cholera t
The results represent three experiments performed with duplicate samples.(Figure 5B left) with fludarabine treatment alone; from
70% to 59% in BIBB-515 (Figure 5A middle) and from
61% to 48% in YM53601 (Figure 5B middle) with rituximab
treatment alone; and from 50% to 34% in BIBB-515
(Figure 5A right) and from 42% to 32% in YM-53601
(Figure 5B right) with their combination treatment. The
data demonstrates that either BIBB-515 or YM-53601
can lower cellular cholesterol levels, up-regulate CD-20
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Figure 5 Effect of BIBB-515 and YM-53601 on chemoimmuno-sensitivity. MEC-2 cells were treated with 10 μM fludarabine (F), 10 μg/ml
rituximab (R) or their combinations (F + R) in the presence or absence of 10 μM either BIBB-515 (B, panel A) or YM-53601 (Y, panel B) for 3 days,
and analyzed cell viability by MTT assay. The values of treated with BIBB-515 or YM-53601 samples (n = 16) were statistically different from the
controls (C). *P < 0.05. **P < 0.01.
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cells
TAK-475 (Lapaquistat) is another squalene synthase in-
hibitor that has been used as a cholesterol lowering drug
in Phase III clinical trials in Europe and the United
States [39]. To investigate the effect of TAK-475 on
chemoimmuno-sensitivity, we firstly treated MEC-2
cells with 10 μM TAK-475 for 3 days, and explored its
effect on CD-20 expression and distribution. As shown
in Figure 6, both CD-20 staining and membrane association
are significantly increase in TAK-475 treated (Figure 6C
and D) compared with those controls (Figure 6A and B).
Next, we analyze the effect of TAK-475 on MEC-2 cell
chemoimmuno-sensitivity. As shown in Figure 6E,
TAK-475 enhances chemoimmuno-sensitivity of fludara-
bine, rituximab and their combinations. With TAK-475,
cell viability was decreased from 72% to 40% with fludara-
bine treatment alone, from 80% to 59% with rituximab
treatment alone, and from 41% to 26% with their combin-
ation treatment.
BIBB-515 and TAK-475 enhance chemoimmuno-sensitivity
in the PBMCs
Our results show that cholesterol lowering agents enhance
chemoimmuno-sensitivity in MEC-2 cells. To investigate
the potential cholesterol lowering agents for CLL
chemoimmuno-therapy, we isolated the PBMCs fromCLL patients, treated the cells with 10 μM fludarabine,
10 μg/ml rituximab, or their combinations in the pres-
ence or absence of either 10 μM BIBB-515 or TAK-475
for 3 days, and determined cell viability by Trypan blue
staining. With BIBB-515, cell viability was reduced from
75% to 63% with fludarabine alone, from 85% to 73% with
rituximab alone, and from 76% to 57% with their combi-
nations (Figure 7A). With TAK-475, cell viability was
reduced from 66% to 58% with fludarabine alone, from
82% to 66% with rituximab alone, and from 64% to 49%
with their combinations (Figure 7B). These results de-
monstrate that either BIBB-515 or TAK-475 enhances
chemoimmuno-sensitivity in the PBMCs from CLL
patients.
Discussion
Cholesterol plays an essential role in the stability and
architecture of the plasma membrane and in the involve-
ment of vesicle traffic and receptor signaling [40,41].
Emerging data from profiling of cancer tissues and ani-
mal models [42-44] as well as in vitro cancer cell lines
[45] demonstrate that cholesterol is capable of regulating
cell proliferation, migration, and signaling pathways in
carcinogenesis, tumor development and chemotherapy
resistance. Recognizing cholesterol as an important factor
contributing to cancer development, many researchers






























































Figure 7 Effect of BIBB-515 and TAK-475 on chemoimmuno-sensitivity in the PBMCs from CLL patients. The PBMCs were treated with or
without 10 μM fludarabine (F), 10 μg/ml rituximab (R) or their combinations (F + R) in the presence or absence of 10 μM either BIBB-515 (B, panel
A) or TAK-475 (T, panel B) for 3 days, and cell viability was determined by Trypan blue live-dead cell staining. The values of treated with BIBB-515
(n = 10) or TAK-475 (n = 6) samples were statistically different from the controls (C). *P < 0.05. **P < 0.01.


























Figure 6 Effect of TAK-475 on CD-20 expression and chemoimmuno-sensitivity. MEC-2 cells were treated with 10 μM TAK-475 (T) for 3 days,
processed for double immunostaining, and photographed by confocal microscope (A-D). The results represent three experiments performed with
duplicate samples. The cells were also treated with 10 μM fludarabine (F), 10 μg/ml rituximab (R) or their combinations (F + R) in the presence or
absence of 10 μM TAK-475 for 3 days, and then analyzed cell viability by MTT assay (E). The values of treated with TAK-475 samples (n = 16) were
statistically different from the controls (C). *P < 0.05. **P < 0.01.
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lowering agents, inhibit mevalonate metabolism and
exhibit antitumor effects against various cancer cell
lines [27-29]. Using lovastatin, we reported here that
lowering cholesterol exhibited increased chemosensitivity
in fludarabine-treated MEC-2 cells, but had no effect on
immunotherapy in rituximab-treated cells (Figure 3).
Earlier data from in vitro [32] and in vivo [46] also
showed that statins do not influence clinical response
and B cell depletion after rituximab treatment because sta-
tins induce conformational changes in CD-20 molecules
and impair rituximab-mediated complement-dependent
cytotoxicity.
CLL cell killing by rituximab requires cross linking of
CD-20, which induces redistribution of CD-20 to lipid
rafts. Lipid rafts are specialized microdomains of the
plasma membrane that are enriched in sphingolipid and
cholesterol, and play an important role in the initiation
of many anticancer drug-induced signaling pathways
and toxicological effects. Anticancer drugs are able to
suppress cell growth and induce apoptosis of tumor cells
through disrupting lipid raft integrity [32,47]. The redis-
tribution of CD-20 may result in lipid raft disruption,
activate or deactivate raft-associated proteins, such as
death receptors and protein kinases in apoptotic pathway
which are correlated with efficiency of complement-
dependent cytotoxicity and antibody-dependent cell-
mediated cytotoxicity. Rituximab and other anti-CD-20
antibodies are currently key drugs in CLL chemoimmuno-
therapy. Although statins have antitumor activity, they are
clearly unsuitable for enhancement of chemoimmuno-
sensitivity of lymphomas and leukemias.
To search for new agents that can lower cellular chol-
esterol, and do not negatively interfere with CD-20 and
rituximab-mediated activity, we chose three compounds
that can inhibit squalene synthase (YM-53601 and TAK-
475) or oxidosqualene cyclase (BIBB-515). These enzymes
are further downstream steps in cholesterol biosynthetic
pathway (Figure 2). By confocal microscopy, our results
indicate that treatment of MEC-2 cells with YM-53601,
BIBB-515 or TAK-475 did significantly up-regulate CD-20
surface expression and membrane-association (Figures 4
and 6). One recent study has shown that farnesyltransfer-
ase inhibitors may up-regulate CD-20 at mRNA and
protein levels and improve anti-CD-20 monoclonal
antibody-mediated activation of complement-dependent
cytotoxicity [48]. Earlier reports demonstrated that cy-
tokines (interleukin-4, granulocyte-macrophage colony-
stimulating factor, or interferon-α) also increase CD-20
surface expression [46,49]. Taken together, our data and
those results indicate that the agents inhibiting downstream
steps of cholesterol biosynthesis and other cholesterol-
associated pathways could positively regulate CD-20
expression and its antibody-mediated signaling.Our observations indicate for the first time that BIBB-
515, YM-53601 and TAK-475 significantly inhibit their
respective enzymes in the pathway of cholesterol biosyn-
thesis to lower cellular cholesterol levels, and that targeting
these enzymes could positively affect CD-20 distribution
and its antibody-mediated activation in contrast to statins.
Lowering cellular cholesterol levels with statins has
been shown to induce apoptosis, [24-26] and have im-
portant antitumor activity in some malignancies [27-29].
Our experiments demonstrate that the cholesterol
lowering agents BIBB-515, YM-53601 and TAK-475
render chemoimmuno-therapy resistant cells sensitive to
chemoimmuno-therapy, and enhance cell chemoimmuno-
sensitivity and apoptosis (Figures 5 and 6). These results
validate the concept that cholesterol reduction using en-
zymatic inhibitors is different to the action of statins,
probably due to different mechanism of activation of
CD-20 dependent pathways.
We have also observed the effect of BIBB-515 and
TAK-475 on chemoimmuno-sensitivity in the PBMCs
from CLL patients. These cells from different patients
show differences in response to three-day chemoimmuno-
therapeutic drug treatment. The PBMCs from two pa-
tients (total 14 patients) weakly responded to fludarabine,
and three patients are very weak in response to rituximab;
however, all of these patient cells showed a 5-30% increase
of chemoimmuno-sensitivity with cholesterol lowering
agents. In these patients, two patients had undergone
fludarabine treatment and one had undergone a round
of chlorambucil and rituximab treatment. These
PBMCs also show increased chemoimmuno-sensitivity
with fludarabine, rituximab or their combinations in
the presence of cholesterol lowering agents. Although
cells treated with multiple drugs could cause pleiotropic
effects, it is important that the combinations of BIBB-515,
YM-53601 or TAK-475 and chemoimmuno-therapeutic
drugs are synergistic effects. Our findings regarding the
role of cholesterol on chemoimmuno-therapy along with
recent reports in different types of cancer cells [18-29]
highlight the relevance of cholesterol modulation in can-
cer therapy.
Decreased cell growth by lowering cellular cholesterol
levels with statins in different cancer cells have been
previously shown, we demonstrate that the mechanism
of cholesterol modulation by other inhibitors is import-
ant because statins negatively affect CD-20 expression
and antibody-mediated cell killing through CD-20. Our
data demonstrate that BIBB-515, YM-52601 and TAK-475
acting at squalene synthase or oxidosqualene cyclase re-
duce cellular cholesterol levels, and inhibit cell growth
leaving a CD-20 mediated pathway intact. Compensatory
changes in membrane lipid composition as a result of
treatment with these cholesterol synthesis inhibitors are
an area we are investigating. Taken together, our results
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is a novel and viable approach to both cancer therapeutics
and reversal of chemoimmuno-therapy resistance.
Material and methods
Materials
All chemicals were purchased from Sigma-Aldrich (St
Louis, MO, USA) or Fisher Scientific (Pittsburgh, PA, USA)
unless specified otherwise. Ficoll-Paque Plus was obtained
from Amersham Biosciences (Piscataway, NJ, USA). The
media for cell culture were purchased from GIBCO (Grand
Island, NY, USA). The anti-CD-20 APC antibody was
obtained from eBiosciences (San Diego, CA, USA).
CellTiter 96® Non-Radioactive Cell Proliferation Assay
kit (MTT) was purchased from Promega (Madison,
WI, USA). Fludarabine was obtained from Teva Paren-
teral Medicines, Inc (Irvine, CA, USA). Rituximab was
obtained from Genentech (South San Francisco, CA,
USA). BIBB-515 and YM-53601 were purchased from
Cayman Chemical Company (Ann Arbor, MI, USA). TAK-
475 was obtained from Chemzon Scientific (Montreal,
Quebec, Canada).
Cell culture, PBMC isolation and cell treatment
MEC-2 cells were cultured in DMEM/F-12 media with
10% FBS. Cells were grown at 37°C in 5% CO2. Choles-
terol lowering agents (BIBB-515, YM-53601 or TAK-475)
were added to the cultures at 10 μM final concentration
in the presence or absence of fludarabine (10 μM), rituxi-
mab (10 μg/ml) or their combinations for 3 days. Treated
cells were used for analysis according to experimental
design.
Blood was obtained from CLL patients as defined by
NCI96 criteria 28 [50] following receipt of written in-
formed consent under an IRB protocol approved by the
University of Missouri-Columbia. PBMCs were isolated
from whole blood immediately following donation using
Ficoll density gradient centrifugation. Isolated cells were
treated with test compounds as experimental designed and
incubated at 37°C and 5% CO2 in RPMI-1640 media for
3 days. Cells were counted manually on a hemocytometer
with Trypan blue solution before treatment, and at 1, 2,
and 3 days after treatment to determine cell viability.
Total cholesterol analysis
Three million MEC-2 cells in the experiments were har-
vested, and 6 μl of standard cholesterol (1 mg/ml of
chloroform) was added to the samples. Total cholesterol
was extracted by the method of Bligh and Dyer [51].
The resulting organic lower phase was withdrawn and
evaporated under a stream of N2. One milliliter of meth-
anolic potassium hydroxide was added to the tubes, and
the samples were heated at 80°C for 1 hour. The tubes
were sonicated several times during saponification. Aftercooling down, 2 ml of HPLC-grade water was added and
the sterols were recovered by extracting the mixture 3
times with 3 ml hexane. The hexane extracts were
pooled and dried down under N2. After complete dry, the
samples were re-dissolved in 70 μl pyridine. The samples
were derivatized by adding 30 μl N-trimethylsilyl-N-
methyltrifluoroacetamide with trimethylchlorosilane and
incubating at 50°C for 1 hour. The solvents were com-
pletely dried and re-dissolved in 75 μl of chloroform. Gas
chromatography mass spectrometry (GC/MS) analysis
was performed at the Kansas Lipidomics Research Center
on an Agilent 6890 N GC coupled to an Agilent 5975 N
quadrupole mass selective detector. The data were col-
lected and processed with Agilent Chemstation.
Confocal microscopy
MEC-2 cells were treated with various compounds for
3 days, washed in cold medium, and fixed with 4% para-
formaldehyde in 100 mM phosphate buffer on ice. The
fixed cells were washed twice with 1% BSA in PBS (BSA
buffer). The cells were blocked for 15 minutes in 5%
mouse serum in PBS and washed with BSA buffer. The
cells were stained for 1 hour with anti-CD-20 APC
antibody and cholera toxin-B FITC. Wet-mount slides
were prepared, and the samples were viewed by a Zeiss
510 META laser scanning confocal microscope and
photographed by LSM 4.2 software.
Cell viability assays
MEC-2 cells were plated in 96-well assay plates at a
concentration of 10,000 cells per well in 100 μl of culture
medium with test compounds according to experimental
designed. After adding the agents, the cells were cultured
at 37°C for 3 days, and cell viability was determined using
Promega’s CellTiter 96® Non-Radioactive Cell Proliferation
Assay kit (MTT) according to the manufacturer’s instruc-
tions. Absorbance at 570 nm was recorded using a Biotek
Synergy H4 Hybrid Reader (Winooski, VT). MEC-2 cells
and PBMCs were stained with Trypan blue solution, and
dead and alive cells were counted after treatment to deter-
mine cell viability.
Measurement of DNA fragmentation
According to experimental designed, treatment of MEC-2
cells were harvested and centrifuged at 1,500 g for 2 min,
and the pellets were resuspended in 0.5 ml of lysis buffer
containing 5 mM Tris-HCl, pH 8.0, 20 mM EDTA, and
0.5% Triton X-100 and placed on ice for 15 min. The sam-
ples were then centrifuged at 12,000 g for 20 min, and the
supernatant containing DNA cleavage products in the
same amount of cellular proteins was precipitated over-
night using isopropyl alcohol. The samples were centri-
fuged at 24,446 g for 20 min. Pellets were resuspended in
Tris-EDTA buffer and digested with 0.2 mg/ml proteinase
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ments were separated on a 1.5% agarose gel, visualized
with ethidium bromide, and photographed using the
Bio-Rad image system.
Data analysis
Statistical analysis was done using Sigma plot 12. The
difference in the mean values among treatment groups
to the controls were analyzed by one way analysis of
variance.
Abbreviations
CLL: Chronic lymphocytic leukemia; PBMC: Peripheral blood mononuclear
cell; HMG-CoA: Hydroxy-3-methylglutaryl-coenzyme A.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
IB, CF, and CH conceived the experimental design. IB, TJ, and CH performed
the experiments and analyzed the data. VV, RB, MA, and RS collected the
patient samples and analysis. IB, CF and CH interpreted the data. CH and CF
wrote the paper. All authors read and approved the final manuscript.
Acknowledgements
We thank the Kansas Lipidomics Research Center for Lipid analysis, Dr.
Alexander Jurkevic at the Molecular Cytology Research Core Facility at the
University of Missouri-Columbia for the help of confocal microscopy, and
clinical trials office Lynn walker for patient bloods.
Author details
1Division of Hematology/Oncology, Department of Medicine, School of
Medicine, University of Missouri, Columbia, MO 65212, USA. 2Cancer Center,
Saint Louis University, Saint Louis, MO 63110, USA. 3Division of Hematology/
Oncology, Department of Internal Medicine School of Medicine, and Cancer
Center, Saint Louis University, 3655 Vista Avenue, St. Louis, MO 63110-2539,
USA.
Received: 28 July 2014 Accepted: 14 September 2014
Published: 26 September 2014
References
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin
2013, 63:11–30.
2. Chiorazzi N, Hatzi K, Albesiano E: B-cell chronic lymphocytic leukemia, a
clonal disease of B lymphocytes with receptors that vary in specificity
for (auto)antigens. Ann NY Acad Sci 2005, 1062:1–12.
3. Hallek M: Chronic lymphocytic leukemia: 2013 update on diagnosis, risk
stratification and treatment. Am J Hematol 2013, 88:803–816.
4. Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J
Med 2005, 352:804–815.
5. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S: From
pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev
Cancer 2010, 10:37–50.
6. Caligaris-Cappio F, Hamblin TJ: B-cell chronic lymphocytic leukemia: a bird
of a different feather. J Clin Oncol 1999, 17:399–408.
7. Fischer K, Cramer P, Busch R, Böttcher S, Bahlo J, Schubert J, Pflüger KH,
Schott S, Goede V, Isfort S, von Tresckow J, Fink AM, Bühler A, Winkler D,
Kreuzer KA, Staib P, Ritgen M, Kneba M, Döhner H, Eichhorst BF, Hallek M,
Stilgenbauer S, Wendtner CM: Bendamustine in combination with
rituximab for previously untreated patients with chronic lymphocytic
leukemia: a multicenter phase II trial of the German Chronic
Lymphocytic Leukemia Study Group. J Clin Oncol 2012, 30:3209–3216.
8. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, Cazin B,
Navarro M, Leblay R, Leporrier M, Jaubert J, Lepeu G, Dreyfus B, Binet JL,
Travade P: Chlorambucil in indolent chronic lymphocytic leukemia. N Engl
J Med 1998, 21:1506–1514.9. Robak T, Bloński JZ, Kasznicki M, Blasińska-Morawiec M, Krykowski E,
Dmoszyńska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L,
Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasiński I, Zdziarska B,
Kotlarek-Haus S, Potoczek S, Grieb P: Cladribine with prednisone versus
chlorambucil with prednisone as first-line therapy in chronic lymphocytic
leukemia: report of a prospective, randomized, multicenter trial. Blood
2000, 96:2723–2729.
10. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, Hines J,
Threatte GA, Larson RA, Cheson BD, Schiffer CA: Fludarabine compared
with chlorambucil as primary therapy for chronic lymphocytic leukemia.
N Engl J Med 2000, 343:1750–1757.
11. Hillmem P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, Sirard C,
Mayer J: Alemtuzumab compared with chlorambucil as first-line therapy
for chronic lymphocytic leukemia. J Clin Oncol 2007, 25:5616–5623.
12. Maloney DG, Grillo-López AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA,
Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T,
Levy R: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy
in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood
1997, 90:2188–2195.
13. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R,
Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC:
Combination chemoimmunotherapy with pentostatin,
cyclophosphamide, and rituximab shows significant clinical activity with
low accompanying toxicity in previously untreated B chronic
lymphocytic leukemia. Blood 2007, 109:405–411.
14. Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, Zelenetz
AD, Horgan D, Gencarelli A, Panageas KS, Scheinberg DA, Weiss MA:
Pentostatin, cyclophosphamide, and rituximab is an active,
well-tolerated regimen for patients with previously treated chronic
lymphocytic leukemia. J Clin Oncol 2006, 24:1575–1581.
15. Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA,
Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H,
Keating M: Chemoimmunotherapy with fludarabine, cyclophosphamide,
and rituximab for relapsed and refractory chronic lymphocytic leukemia.
J Clin Oncol 2005, 23:4070–4078.
16. Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA,
Cortes J, Lerner S, Keating MJ: Long-term results of the fludarabine,
cyclophosphamide, and rituximab regimen as initial therapy of chronic
lymphocytic leukemia. Blood 2008, 112:975–980.
17. Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P,
Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek
M, Engert A: Fludarabine in combination with alemtuzumab is effective and
feasible in patients with relapsed or refractory B-cell chronic lymphocytic
leukemia: results of a phase II trial. J Clin Oncol 2005, 23:7024–7031.
18. Montero J, Morales A, Llacuna L, Lluis JM, Terrones O, Basañez G, Antonsson
B, Prieto J, García-Ruiz C, Colell A, Fernández-Checa JC: Mitochondrial
cholesterol contributes to chemotherapy resistance in hepatocellular
carcinoma. Cancer Res 2008, 68:5246–5256.
19. Storch CH, Ehehalt R, Haefeli WE, Weiss J: Localization of the human breast
cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and
modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther
2007, 323:257–264.
20. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR: Cholesterol
targeting alters lipid raft composition and cell survival in prostate cancer
cells and xenografts. J Clin Invest 2005, 115:959–968.
21. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M,
Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg
G, Hensens O, Hirshfield J: Mevinolin: a highly potent competitive inhibitor of
hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering
agent. Proc Natl Acad Sci U S A 1980, 77:3957–3961.
22. Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid
lowering–are they clinically relevant? Eur Heart J 2003, 24:225–248.
23. McKenney JM: New cholesterol guidelines, new treatment challenges.
Pharmacotherapy 2002, 22:853–863.
24. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR: Lovastatin
augments apoptosis induced by chemotherapeutic agents in colon
cancer cells. Clin Cancer Res 1999, 5:2223–2229.
25. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS: Simvastatin induces
apoptosis in human colon cancer cells and in tumor xenografts, and
attenuates colitis-associated colon cancer in mice. Int J Cancer 2008,
123:951–957.
Benakanakere et al. Experimental Hematology & Oncology 2014, 3:24 Page 10 of 10
http://www.ehoonline.org/content/3/1/2426. Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS: Combination of atorvastatin
and celecoxib synergistically induces cell cycle arrest and apoptosis in
colon cancer cells. Int J Cancer 2008, 122:2115–2124.
27. Chan KK, Oza AM, Siu LL: The statins as anticancer agents. Clin Cancer Res
2003, 9:10–19.
28. Sassano A, Platanias LC: Statins in tumor suppression. Cancer Lett 2008,
260:11–19.
29. Bardou M, Barkun A, Martel M: Effect of statin therapy on colorectal
cancer. Gut 2010, 59:1572–1585.
30. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ: Blocking
protein geranylgeranylation is essential for lovastatin-induced apoptosis
of human acute myeloid leukemia cells. Leukemia 2001, 15:1398–1407.
31. Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M:
Simvastatin induces apoptosis of B-CLL cells by activation of
mitochondrial caspase 9. Exp Hematol 2003, 31:779–783.
32. Winiarska M, Bil J, Wilczek E, Wilczynski GM, Lekka M, Engelberts PJ, Mackus
WJ, Gorska E, Bojarski L, Stoklosa T, Nowis D, Kurzaj Z, Makowski M,
Glodkowska E, Issat T, Mrowka P, Lasek W, Dabrowska-Iwanicka A, Basak GW,
Wasik M, Warzocha K, Sinski M, Gaciong Z, Jakobisiak M, Parren PW, Golab J:
Statins impair antitumor effects of rituximab by inducing conformational
changes of CD20. PLoS Med 2008, 5:e64.
33. Pelton K, Freeman MR, Solomon KR: Cholesterol and prostate cancer. Curr
Opin Pharmacol 2012, 12:751–759.
34. Gorin A, Gabitova L, Astsaturov I: Regulation of cholesterol biosynthesis
and cancer signaling. Curr Opin Pharmacol 2012, 12:710–716.
35. Danilo C, Frank PG: Cholesterol and breast cancer development. Curr Opin
Pharmacol 2012, 12:677–682.
36. Thurnher M, Nussbaumer O, Gruenbacher G: Novel aspects of mevalonate
pathway inhibitors as antitumor agents. Clin Cancer Res 2012,
18:3524–3531.
37. Ugawa T, Kakuta H, Moritani H, Matsuda K, Ishihara T, Yamaguchi M,
Naganuma S, Iizumi Y, Shikama H: YM-53601, a novel squalene synthase
inhibitor, reduces plasma cholesterol and triglyceride levels in several
animal species. Br J Pharmacol 2000, 131:63–70.
38. Eisele B, Budzinski R, Müller P, Maier R, Mark M: Effects of a novel
2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis
and lipid metabolism in vivo. J Lipid Res 1997, 38:564–575.
39. Stein EA, Bays H, O’Brien D, Pedicano J, Piper E, Spezzi A: Lapaquistat
acetate: development of a squalene synthase inhibitor for the treatment
of hypercholesterolemia. Circulation 2011, 123:1974–1985.
40. Simons K, Ikonen E: How cells handle cholesterol. Science 2000,
290:1721–1726.
41. Luu W, Sharpe LJ, Gelissen IC, Brown AJ: The role of signalling in cellular
cholesterol homeostasis. IUBMB Life 2013, 65:675–684.
42. Krycer JR, Brown AJ: Cholesterol accumulation in prostate cancer: a
classic observation from a modern perspective. Biochim Biophys Acta
1835, 2013:219–229.
43. Hilvo M, Denkert C, Lehtinen L, Muller B, Brockmoller S, Seppanen-Laakso T,
Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M,
Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyötyläinen T,
Kallioniemi O, Iljin K, Oresic M: Novel theranostic opportunities offered by
characterization of altered membrane lipid metabolism in breast cancer
progression. Cancer Res 2011, 71:3236–3245.
44. Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN,
Shirley Liu X, Struhl K: A transcriptional signature and common gene
networks link cancer with lipid metabolism and diverse human diseases.
Cancer Cell 2010, 17:348–361.
45. Das S, Fernandez Matilla M, Dass S, Buch MH, Rawstron AC, Vital EM, Emery
P: Statins do not influence clinical response and B cell depletion after
rituximab treatment in rheumatoid arthritis. Ann Rheum Dis 2013,
72:463–464.
46. Sivaraman S, Venugopal P, Ranganathan R, Deshpande CG, Huang X, Jajeh
A, Gregory SA, O’Brien T, Preisler HD: Effect of interferon-alpha on CD20
antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell
Mol Ther 2000, 6:81–87.
47. Winiarska M, Nowis D, Bil J, Glodkowska-Mrowka E, Muchowicz A, Wanczyk
M, Bojarczuk K, Dwojak M, Firczuk M, Wilczek E, Wachowska M, Roszczenko
K, Miaczynska M, Chlebowska J, Basak GW, Golab J: Prenyltransferases
regulate CD20 protein levels and influence anti-CD20 monoclonal
antibody-mediated activation of complement-dependent cytotoxicity.
J Biol Chem 2012, 287:31983–31993.48. Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD:
Effects of cytokines on CD20 antigen expression on tumor cells from
patients with chronic lymphocytic leukemia. Leuk Res 2000, 24:411–415.
49. Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N,
Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai
K, Suh C, Ogura M: Multicenter phase II study of bendamustine plus
rituximab in patients with relapsed or refractory diffuse large B-cell
lymphoma. J Clin Oncol 2013, 31:2103–2109.
50. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, Rai KR:
National Cancer Institute-sponsored Working Group guidelines for
chronic lymphocytic leukemia: revised guidelines for diagnosis and
treatment. Blood 1996, 87:4990–4997.
51. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 1959, 37:911–917.
doi:10.1186/2162-3619-3-24
Cite this article as: Benakanakere et al.: Targeting cholesterol synthesis
increases chemoimmuno-sensitivity in chronic lymphocytic leukemia
cells. Experimental Hematology & Oncology 2014 3:24.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
